🇬🇧

ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO

Credit: Business Wire- Published 1 week ago
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Presents Final Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin® at ESMO
Advertisement

You are here

You might like